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ABSTRACT 
Objective: To develop a new simple, selective and precise high-performance thin-layer chromatographic method for determination of Dapagliflozin 
(DAPA) in bulk and tablet dosage form. 
Methods: The present study describes the development and validation of a High-performance thin-layer chromatographic method for DAPA. The 
chromatographic separation was carried out on Merck precoated silica gel aluminum plate 60 F254
Results: The chromatographic condition showed a compact band with the retention factor for dapagliflozin as 0.21±0.004. The method was 
validated as per ICH guidelines for linearity, accuracy, precision and robustness. Response was found to be linear in the concentration range of 400 
ng/band to 1200 ng/band with linear regression value of 0.9953 with respect to peak area and concentration value. The LOD and LOQ were found 
to be 1.2083 ng/band and 3.6616ng/band. The percentage assay was found to be 100±0.05.  
 using Chloroform: Methanol (9:1v/v) as mobile 
phase. Quantitative determination of drug was carried out by densitometric scanning of plates at 223 nm using Camag TLC Scanner.  
Conclusion: This method under statistical analysis proved a selective, repeatable and accurate analysis of the drug. This method can be used for 
quantitative analysis of dapagliflozin in the bulk drug and in tablets as the run time is very minimal. 
Keywords: Dapagliflozin, HPTLC, Method development, Validation 




Dapagliflozin (DAPA) is a drug of gliflozin class. Chemically it is (2S, 
3R, 4R, 5S, 6R)-2-(4-chloro-3-(4-ethoxybenzyl) phenyl)-6-
(hydroxymethyl) tetrahydro-2H-pyran-3,4,5-triol (fig. 1) with 
molecular formula of C21H25ClO6 
 
and molecular weight of 
408.875g/mol. It is a white crystalline solid, having a solubility in 
organic solvents like DMSO dimethyl formamide and ethanol. Its 
melting point is 55-60 °C [1]. Dapagliflozin is a selective sodium-
glucose co-transporter subtype 2 (SGLT2) inhibitor with anti-
hyperglycemic activity. Dapagliflozin selectively and potently 
inhibits SGLT2 compared to SGLT1, which is the co-transporter of 
glucose in the gut. Dapagliflozin blocks glucose reabsorption into the 
kidney, resulting in the elimination of blood glucose through the 









Fig. 1: Chemical structure of Dapagliflozin 
 
The literature survey revealed that very few spectroscopic [2, 3], RP-
HPLC [4-13] methods and LCMS/MS [13] methods were reported for 
DAPA. No HPTLC method was reported in the literature so far for 
this drug in commercial pharmaceutical preparations. However, few 
methods were developed for the combination of drugs. A 
comparative evaluation of HPLC and HPTLC estimation was carried 
out for simultaneous determination of dapagliflozin and metformin 
hydrochloride [14] and UV-spectroscopic first derivative and HPTLC 
methods were done to estimate dapagliflozin propanediol 
monohydrate and saxagliptin hydrochloride [15]. This necessitates 
the requirement for the development of newer methods of analysis 
for DAPA so that it can be used in routine analysis. The present 
investigation aimed to develop and validate a method for estimation 
of DAPA in pharmaceutical dosage forms by HPTLC. 
MATERIALS AND METHODS 
Chemicals and reagents 
Dapagliflozin (DAPA) was a generous gift from Micro Labs, 
Bengaluru, India and used as such. Chloroform, water and methanol 
of HPLC grade (Merck Ltd., Mumbai, India) were used. The 
pharmaceutical dosage form used in this study was a tablet, which 
was purchased from local retail pharmacy Bengaluru, India. (Trade 
name OXRA-10 mg/tab manufactured by Sun pharma). 
Camag HPTLC system (Camag, Muttenz, Switzerland) consisting of a 
Camag Linomat V semiautomatic spotting device under nitrogen gas 
flow and Camag TLC scanner III with WinCATS 4 software (version 
4.05, Camag), 100 μL HPTLC sample syringe (Hamilton, Bonaduz, 
Switzerland), Camag UV chamber and a Camag glass twin-trough (10 
cm ×10 cm) development chamber were used. Pre-coated silica gel 
60 F254
Optimization of HPTLC method 
 aluminium plate with 75-125 µm layer thickness, 10x10 cm; 
Merck Germany was used as stationary phase. TLC scanner III with 
winCATS software was used to carry out the densitometric analysis. 
Stock solution 
100 mg of DAPA was weighed and dissolved in methanol and the 
volume was made up to 100 ml to obtain a concentration of 1 
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mg/ml. From this 1 ml was diluted to 10 ml, which was used as 
working standard solution. 
Sample solution 
Tablets was powdered and powder equivalent to 100mg of DAPA was 
weighed accurately, transferred into volumetric flask, sonicated, 
sonicated for half an hour with 20 ml of methanol and diluted to a 
volume of 100 ml to obtain a concentration of 1 mg/ml. From this 1 ml 
was diluted to 10 ml, which was used as a standard working solution. 
Stationary phase 
Merck TLC plates Silica gel 60F (10 x10 cm) 
Selection of mobile phase 
Mobile phase: Trial chromatographic runs were carried out using 8 
µl of standard solution when spotted on TLC plate using CAMAG 
LINOMAT V using nitrogen gas flow to give a concentration of 800 
ng/band. The chromatogram was developed in twin trough chamber 
saturated with mobile phase till the solvent front reached about 7.0 
cm. The plate was removed, air-dried and visualized under CAMAG 
UV chamber. A good resolution with a perfect band was found with 
Chloroform: Methanol in the ratio of 9:1v/v. 
Selection of analytical wavelength 
The standard drug solution of DAPA prepared in methanol was 
scanned in the range of 200-800 nm. The spectrum was recorded. 
DAPA exhibited maximum absorbance at 223 nm. 
Optimization of chromatographic conditions for HPTLC 
Based on the above study, it was concluded that the 
chromatographic separation of DAPA could be achieved under the 
conditions detailed in table 1. Chromatogram of standard solution 
recorded under optimized conditions exhibited well-resolved peaks 
with Rf value
 
 of 0.21±0.004 as shown in the fig. 2. 
 
Fig. 2: Densitogram of standard DAPA 
 
Validation parameters of the developed method 
Linearity 
Five sets of the standard solution of DAPA, 4-12 μl with 2μl 
increment, was spotted on to the chromatographic plate as 
described earlier and the chromatogram was developed and 
scanned at 223 nm. Chromatographic response in terms of area was 
plotted against concentration and a straight-line fit was made 
through the data points by least square regression analysis to get 
linearity plot. From the linearity plot the slop and Y-intercept were 
noted. Further, the correlation coefficient was also calculated. 
Limit of detection (LOD) and limit of quantification (LOQ) 
The LOD and LOQ were calculated using following equations as per 
International Conference on Harmonization guideline for DAPA. 
LOD= 3.3 x σ/S 
LOQ= 10 x σ/S 
Where σ is standard deviation of the response and S is the standard 
deviation of y-intercept of regression lines. 
Specificity 
The chromatogram obtained from the sample run was scanned for 
peak purity analysis. The peak purity of DAPA was assessed by 
comparing their respective spectra at the peak start, apex and peak 
end positions of the spot. The band DAPA in the sample was 
confirmed by comparing Rf 
Precision (Reproducibility) 
value and respective spectra of the 
sample with that of the standard. 
The precision of the method was verified by performing the intraday 
and inter-day precision. The entire linearity range was used to study 
the precision of the method. Precision of the proposed method was 
studied with respect to the intraday and inter-day by estimating the 
corresponding response three times on the same day and on three 
different days over a period of one week, using the same 
chromatographic conditions as described above. The results are 
expressed in terms of relative standard deviation. 
Accuracy (Recovery studies) 
The accuracy of the method was determined by recovery studies using 
standard additions at three different levels (80, 100 and 120%) in the 
formulation. Three determinations were performed at each level, 
using the same chromatographic conditions as described above. 
Robustness 
The robustness of the method was studied with an intentional 
change in the composition of the mobile phase and the values were 
compared with the original chromatographic conditions. Robustness 
of the method was determined in triplicate at a concentration level 
of 800 ng/band and the mean and %RSD of peak area was calculated 
[16]. 
Application of the proposed method for the determination of 
DAPA in tablet 
The content of DAPA in marketed tablet dosage form was estimated 
by the established method. The marketed tablet has the label claim 
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of 10 mg of DAPA. Twenty tablets were weighed and average weight 
was determined, powdered, from this equivalent weight of 100 mg 
DAPA was taken into a 100 ml volumetric flask, containing 15 ml of 
methanol and sonicated for 30 min, filtered through Whatmann 
filter paper No.41 and then the volume was made up to 100 ml with 
methanol. From this 1 ml was diluted to 10 ml, which was used as a 
working standard solution. From this stock solution 8 µl containing 
800 ng/band was spotted on a HPTLC plate and chromatogram was 
developed as described earlier. The analysis was repeated for three 
times and interference for excipients was analyzed. 
RESULTS  
To optimize the HPTLC parameters for DAPA several mobile phases 
such as n-hexane: ethyl acetate, chloroform: methanol combination 
in the varying ratio was tried and the satisfactory result was 
obtained using the mobile phase chloroform and methanol (9:1 v/v). 
with UV detection at 223 nm (table 1). A sharp and symmetrical 
peak was resolved with an Rf of 0.21±0.004 for DAPA (fig. 2). The 
method validation results were satisfactory as per ICH Q2B 
guidelines. The statistical data showed in the table 2 and fig. 3 
indicated that linear relationship between peaks area (AUC) and 
concentration of DAPA standard (ng/band) in the concentration 
range of 400 ng/band to 1200 ng/band showing a good regression 
coefficient of 0.9953 (fig. 4, table 3.). Limit of detection and limit of 
quantification was calculated based on the average value of slope 
and standard deviation of the y-intercept and was found to be 
1.2083 ng/band and 3.6616 ng/band, respectively. The specificity of 
the developed method was established by analysing the sample 
solutions containing standard DAPA and marketed tablets in 
relation to interferences from formulation ingredients (fig. 5). The 
precision was calculated and was expressed in terms of percentage 
relative standard deviation and it was found to be 0.02-0.073% for 
intraday and 0.02-0.06% for inter-day respectively. The results are 
tabulated in table 4. Percentage recovery in terms of accuracy was 
found to be within the limit of 98% to 102% (table 5). Robustness 
was checked by a slight change in the mobile phase composition, 
saturation time. The method was found to be robust since the peak 
area values were not significantly affected for DAPA (table 6). The 
percentage purity is found to be 100±0.05 average of three trials 
(table 7). 
 
Table 1: Optimized chromatographic conditions for HPTLC analysis of DAPA 
Stationary phase Merck TLC plates silica gel 60 F 254 (10x10 cm) 
Mobile Phase Chloroform: Methanol (9:1 v/v) 
Scanner wavelength  223 nm 
Development Chamber Twin Trough Glass Chamber (10 cmX10 cm) 
Band Length and slit dimension 6 mm and 0.5x 0.45 mm 
Software Wincats–version1.4.3 
Development Distance 7.0 cm 
Tank saturation time 30 min 
 







*Mean of five readings 
 
 
Fig. 3: 3D chromatogram for linearity studies of DAPA 
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Fig. 4: Linearity curve for DAPA 
 
Table 3: Statistical data of calibration curves of DAPA by HPTLC 
Parameters Results 
Linearity Range 400-1200 ng/band 
Regression Equation (R2 y = 0.9755x+587.4 ) 





Fig. 5: Specificity of DAPA 
 
Table 4: Precision study of DAPA by HPTLC analysis 
No. Drug level DAPA (ng/band) Intra day 
average peak area
Inter day 
* average peak area
%RSD for intra day 
* 
%RSD for intra day 
1 400 952 954 0.020 0.054 
2 750 1202 1206 0.045 0.060 
3 1000 1375 1389 0.073 0.028 
4 1250 1566 1587 0.035 0.074 
5 1500 1745 1735 0.054 0.055 
*Mean of three readings, %RSD= Percentage Relative standard deviation 
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Table 5: Recovery studies of DAPA by HPTLC studies 
Amount of the drug 
analysed (ng/band) 











800 640 1440 1440.12 102±1.7 1.6 
800 800 1600 1600.84 99.95±0.05 0.05 
800 960 1760 1760.24 99.98 ±0.02 0.02 
*mean of three readings,±standard Deviation, %RSD= Percentage Relative standard deviation 
 
Table 6: Robustness of the method for DAPA 
Parameters Rf* Amount* Amount detectedspotted (ng/band) * %RSD (ng/band±SD*) 
Chloroform: Methanol 8.9:1.1 v/v 0.21 800 789±4.04 0.05 
Chloroform: Methanol 9.1:0.9 v/v 0.22 8000 801±5.13 0.06 
*
 
mean of three readings,±standard deviation, %RSD= Percentage Relative standard  
Table 7: Content of DAPA in tablets 
Drug Label claim Amount found expressed in percentage* 
DAPA (OXRA) 10 mg 100±0.05 
 *mean of three readings,±standard deviation 
 
DISCUSSION 
Chromatographic technique and spectrophotometric methods are 
most commonly used techniques in pharmaceutical analysis. 
Development of spectrophotometric method involve optimization of 
fewer parameters whereas development of chromatographic 
method specifically HPLC method involves optimization of longer 
number of parameters like mobile phase (type of solvent and their 
proportion) buffers (type of buffers, pH, buffer strength), peak 
modifiers (types and concentration), flow rate and isocratic/ 
gradient apart from optimization of detector parameters. Hence 
conventional trial and error approach will be time-consuming even 
for experienced analyst. Hence a novel, simple and precise high-
performance thin-layer chromatographic (HPTLC) method coupled 
with densitometer, was developed for the estimation of DAPA in the 
pharmaceutical dosage form. 
DAPA is a selective sodium-glucose co-transporter subtype 2 
(SGLT2) inhibitor with anti-hyperglycemic activity. Many 
spectrophotometric methods [2-3] and chromatographic methods 
[4-13] have been reported for estimation of DAPA in bulk and 
formulation. In combination, DAPA has to be analysed by 
chromatographic methods [14, 15]. A work carried out by Sally et al. 
[14] used acetonitrile: ammonium acetate:10% acetic acid (9:0.9:0.1, 
v/v) as the mobile phase at 225 nm. In another study reported by 
Parmar et al. [15] carried out for simultaneous estimation of DAPA, 
propanediol and saxagliptin Hydrochloride (SAXA) using 
Chloroform: Ethyl acetate: methanol: ammonia (6:2:2:2 Drops) as 
Mobile Phase and 210 nm as detector wave length, the Rf value of 
DAPA and SAXA was found to be 0.30 and 0.54 respectively.  
No HPTLC method was reported in the literature so far for this drug 
in commercial pharmaceutical preparations. In the present study, a 
simple HPTLC method has been developed, The solvent system: 
Chloroform: Methanol in the ratio of 9:1v/v. of 8 µl exhibited well-
resolved peaks with Rf value of 0.21±0.004 as shown in the fig. 2 at 
223 nm when carried under optimized conditions as listed in the 
table 1. The statistical data showed a good linear relationship in the 
concentration range of 400 ng/band to 1200 ng/band with a 
regression coefficient of 0.9953. The LOD and LOQ was found to be 
1.2083 ng/band and 3.6616 ng/band respectively. The precision in 
terms of intraday and inter-day was calculated and was expressed in 
terms of percentage relative standard deviation and it was found to 
be 0.02-0.073% for intraday and 0.02-0.06% for inter-day 
respectively and was found to be within standard value as shown in 
the table 4. The low values of %RSD showed that the method is 
precise. Percentage recovery in terms of accuracy was found to be 
within the limit of 98%to 102% as tabulated in the table 5. 
Robustness was checked by a slight change in the mobile phase 
composition, saturation time and results are tabulated in the table 6. 
The method is not altered by changing the method parameters like 
mobile phase composition, chamber saturation time and scanning 
wavelength, which proves that the method is robust. The work was 
applied to estimate DAPA in tablet dosage form, the percentage 
purity was found to be 100±0.05 as shown in the table 7. The 
validated method showed that the drug content separated with no 
interfering peaks generated by the excipients in the marketed 
formulation, as shown in the fig. 5. The method is versatile and 
simple for the analysis DAPA in pure and pharmaceutical 
formulations. The method was found to obey all the validation 
parameters as per the ICH guidelines. The method confirms minimal 
use of the mobile phase with a short run time compared to other 
reported analytical methods. This validated method can be used for 
quality control laboratories for the routine quantitative analysis of 
API and tablets of DAPA. 
CONCLUSION 
Based on the studies conducted and the results obtained, it can be 
concluded that the developed HPTLC method is simple, selective, 
precise, sensitive and accurate. The developed and validated method 
may be used for the determination of DAPA in both bulk drug and 
tablet dosage forms. The excipients used in the formulation were 
also not interfering in the analysis. The method can also minimize 
the time and cost of analysis as several samples can be analysed 
simultaneously with a minimum amount of mobile phase. The meth-
od does not require expensive chemical and solvents and can be 
used as an alternative for existing HPLC methods.  
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